(C) Common Dreams
This story was originally published by Common Dreams and is unaltered.
. . . . . . . . . .
Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform [1]
['Rachel Cohrs', 'Adam Feuerstein', 'Damian Garde', 'Kate Zernike', 'Olivia Goldhill']
Date: 2022-01-25
An insulin production line at a factory of Novo Nordisk, which increased its lobbying spending last year as lawmakers took aim at high insulin costs.
WASHINGTON — As lawmakers took aim at high insulin costs, two major insulin manufacturers increased their lobbying spending last year, according to new federal disclosures.
Insulin has become the poster child for dysfunction in the drug pricing debate, and lawmakers are considering enacting insulin-specific policies including allowing Medicare to negotiate prices for all insulin products and capping out-of-pocket monthly costs for patients in Medicare and the private insurance market.
[END]
---
[1] Url:
https://www.statnews.com/2022/01/25/insulin-giants-eli-lilly-and-novo-nordisk-boosted-their-lobbying-spending-as-democrats-eyed-pricing-reform/
Published and (C) by Common Dreams
Content appears here under this condition or license: Creative Commons CC BY-NC-ND 3.0..
via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/commondreams/
